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1. Introduction 
1.1  Influenza 
Influenza has been a historically deadly virus and remains a serious health threat that can 
affect all populations. In 1918-19, a deadly strain of the influenza virus, known as the 
Spanish Flu, shook the world, resulting in the greatest pandemic in recorded history, 
killing approximately 21 million people8. Pandemic flu refers to the introduction of a 
novel virus strain that a large proportion of the population has not previously been 
exposed to, and therefore does not have pre-existing immunity9. These strains are often 
introduced via zoonotic transfer from animals such as pigs and birds. When this happens, 
morbidity and mortality from the virus is greatly increased. More recently, during the 
2009 swine flu pandemic the A/California/7/2009 (H1N1) strain of the virus was 
responsible for 151,700 and 575,400 deaths worldwide8. A study conducted in California 
in response to this epidemic found a disproportionate amount of cases, including illnesses 
and deaths, were in the obese population7. The authors of that study concluded that 
obesity stands alone as an independent risk factor for morbidity and mortality from 
pandemic influenza. In a study conducted by Sheridan et al. 2011, obesity was found to 
be associated with an impaired adaptive immune response to influenza vaccination2. 
Body mass index was found to correlate with a greater decline in antibody response 12 
months post vaccination as compared to healthy weight individuals.  
Beside pandemic flu, seasonal influenza, which refers to circulating annual 
influenza strains that could have minor changes in their protein structures year-to year, 
remains a serious health threat.  Seasonal influenza can affect virtually all populations 
because of its relative ease of transmission via droplets from infected persons coughing, 
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sneezing or talking. The flu season spans from October to May each year in the northern 
hemisphere. The virus has been known to be especially harmful to very young children, 
the elderly, pregnant women and persons with specific chronic medical conditions such 
as immunodeficiency diseases, asthma and chronic heart or lung diseases and more 
recently obesity.1 Annual vaccination is still the primary method of defense in terms of 
decreasing the impact of the influenza infection on a given population.  
1.2  Vaccine and Adaptive Immunity 
The influenza vaccine is usually administered with an intramuscular injection every year 
to protect people from what research has projected to be the most common circulating 
strains that season10. Usually the vaccine contains inactivated forms of one influenza A 
H1N1 strain, one influenza A H3N2 and one or two influenza B strains, making the 
vaccine either trivalent or quadrivalent. The vaccine is administered to help the body 
prepare for the potential of actually contracting the virus from the environment, using the 
bodies adaptive immunity. 
The body’s immune system is comprised of two distinct segments, the innate and 
the adaptive immunity. This innate immunity has a broader response and is comprised of 
lymphocytes like macrophages and natural killer cells. The adaptive immunity is more 
specific and utilizes B-cells with the help of T-cells to identify antigens and create 
specific antibodies also known as immunoglobulins. When a vaccine is administered, 
naïve B-cells are activated by binding to the antigen. T helper cells identify antigen 
presenting B-cells and secrete cytokines which activate the differentiation and 
proliferation of antibody producing plasma cells and memory B-cells. If the same 
pathogen comes back, memory B-cells exhibit a fast and specific response to the antigen 
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by releasing antigens that bind to the virus, preventing them from binding with other cells 
in our body and tagging them for destruction. The most common immunoglobulin is 
IgG1 which responds primarily to soluble protein antigens like viruses11.  
1.3  Obesity 
This adaptive immune response was found to be impaired in obese individuals, in 
response to the influenza virus.2 This finding has some serious implications because there 
is an obesity epidemic in the U.S. where more than one third of the adult population is 
considered obese or extremely obese (BMI of 30+ and BMI of 40+ respectively) and over 
two thirds of the U.S. adult population is considered to be overweight or obese.3  
Obesity is associated with systemic inflammation caused by hypertrophy of 
adipose tissues, especially visceral adipose, that outgrow their matrix. This increased 
adipocyte growth results in the secretion of inflammatory cytokines like IL-6 and TNFα 
and chemokines which recruit macrophages to the adipose tissue, further propagating the 
secretion of inflammatory cytokines.12 The release of these inflammatory cytokines like 
IL-6 and TNFα have been found to reduce systemic insulin sensitivity by impairing the 
insulin signaling pathway.4 Obesity is also associated with an increase in leptin secretion 
and is associated with a decrease in adiponectin, which may also play a role in impairing 
the body’s metabolic condition. 
The systemic nature of these metabolic changes suggests that it can also affect 
immune function and other important bodily functions. Not every individual who is 
obese, meaning they have a BMI of 30 or greater, exhibits these kinds of inflammatory 
responses. Obese individuals who are metabolically healthy can also be identified. 
However, obese individuals who are exhibiting these inflammatory responses to 
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increased adiposity are at a higher risk of experiencing further complications such as 
cardiovascular disease, metabolic syndrome and type-2 diabetes.4 
1.4  Type-2 Diabetes: 
A strong association between obesity and type-2 diabetes exists, as excess weight has 
been established as a risk factor for type-2 diabetes (T2D). The underlying mechanism is 
again associated with the inflammatory response that is experienced in hypertrophic 
adipose environments. The release of inflammatory cytokines from adipocytes impairs 
the insulin signaling pathway, preventing the pathway from signaling the translocation of 
GLUT-4 to the cell membrane. GLUT-4 is a glucose transporter which allows the 
passage of glucose from the blood into the cell. This impairment means that more and 
more insulin is required to allow glucose to enter into the cells and eventually the cells 
can become resistant to insulin.12 Insulin resistance in the hallmark of T2D which leads to 
having a fasting blood glucose of 125mg/dL or higher, where the normal level is between 
75-100mg/dL.  
Given the close association between obesity and T2D, and that obesity is 
associated with an impaired immune response to the influenza vaccine, it may be 
expected that type-2 diabetics would experience a similar response to the vaccine. 
However, when looking into the effects of diabetes on antibody response to the influenza 
vaccine, Sheridan et al. found that there was no significant difference between the 
responses when considering diabetes alone as the risk factor.5 This poses a new question: 
What is the difference between obese individuals who are metabolically healthy and 
obese individuals treated with a diabetic drug in their ability to response to the influenza 
vaccine? 
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1.5  Metformin 
One thing to consider when differentiating between obese individuals and type-2 
diabetics is that, type-2 diabetics often take medications to control their blood glucose. 
Metformin is the most widely prescribed first medication for patients with T2D, and it 
was not considered in the Sheridan et al. study. Metformin plays an important role in 
increasing insulin sensitivity, through its activation of AMPK, which in the liver 
decreases hepatic glucose production, induces fatty acid oxidation and increases GLUT4 
expression on cellular membranes in the skeletal muscle.6 There is also some evidence to 
suggest that metformin has a direct effect on the metabolism of adaptive immune cells, 
potentially increasing their fatty acid oxidation, making their glucose metabolism more 
efficient.13  
1.6  Aims and Hypothesis 
In previous studies, the antibody response to the trivalent influenza vaccine at 30 days 
and 12 months post vaccination was analyzed. Subjects were vaccinated between Sept-
Oct, and as the peak of the flu season is usually somewhere between December and 
March10, a mid-point between 30 days and one year post vaccination would be important 
to test. It is also important to consider the metabolic profiles of the subjects and whether 
metformin use can influence the antibody response. Therefore, we initiated an experiment 
into the investigation of the effect of time and metabolic state (diabetic or non-diabetic) 
on the humoral and cell mediated immune responses to the A/California/7/2009 (H1N1) 
pdm09-like virus. We hypothesized that treatment of metformin may normalize the 
metabolism of the immune cells, therefore their antibody responses may be higher 
compared with obese people not treated with metformin. 
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2. Material and Methods: 
2.1  Study design and subjects  
Study participants were selected from an ongoing prospective observational study carried 
out by the Beck Lab at the UNC Family Medicine clinic. Samples from year 8 of the 
study, during which the 2016-17 trivalent vaccine was administered, were called in for 
three blood draws at consistent time points. The three different time points were 
classified as “Day 0”, which was pre-vaccination, 30 days post vaccination and 6 months 
post vaccination. Patients were compensated for their participation and were selected to 
match age, sex and race across three different groups: healthy weight (HW, n=6), obese 
nondiabetic (OH, n=5) and obese diabetic (OD, n=4). All subjects were white non-
hispanic females ages 37 – 58. All obese diabetics were taking metformin and all healthy 
weight and obese nondiabetics were not. Demographic data displayed in Table 5.1.  
2.2  Preparation of Virus and Serum Samples 
Virus was inactivated using b-propiolactone and hemagglutination titer (HAU) was 
measured to be 80HAU/50µL. All serum samples were treated with receptor destroying 
enzyme (RDE) and diluted in physiological saline.  
2.3  ELISA - enzyme-linked immunosorbent assay of IgG1 
IgG 1 antibody was quantified using enzyme-linked immunosorbent assay using 
A/California/7/2009 (H1N1) strain. This strain was chosen because it was found in both 
the 2015 and 2016 trivalent influenza vaccine. Virus was diluted in a 
carbonate/bicarbonate buffer and coated onto micro-titration plates. Wells were blocked 
using a carbonate based milk protein buffer. Plates were washed with PBS-tween (PBSt). 
Serum serial dilutions were prepared in PBS based milk protein buffer and allowed to 
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react with virus. Plates were again washed with PBSt. Goat anti-human IgG 1 antibody 
was diluted in PBS based milk protein buffer and was added to plates and allowed to bind 
to human antibody. Plates were washed and binding was detected using peroxidase 
substrate. Color intensity was measured and quantified using a plate reader to measure 
absorbance at wavelength 450nm. The internal positive control was used on every plate 
and all three time points for each patient was measured on the same plate.  
2.4 HAI - haemagglutination inhibition assay 
HAI assays were conducted to determine the level of antibodies in serum as previously 
described.5 RDE-treated serum was incubated in duplicate in a 96 well plate for 15 min at 
room temperature after making serial dilutions of the serum down the plate. After a one 
hour incubation at 4°C with either 0.5% turkey red blood cells, HAI titer was determined 
by the reciprocal dilution of the last well. Positive controls were included on each 
individual plate. An HAI titer of 1:40 is considered to be the threshold for seroprotection 
against influenza, while a 4-fold increase in HAI titers from pre-vaccination to post-
vaccination is considered seroconversion.5 
2.5  Statistical Analysis 
Associations between baseline variables and antibody response at all three time points 
were assessed using Kruskal–Wallis test for categorical variables (metformin and 
menopause status). A two-way Anova was conducted on ELIZA relative absorbance 
values and HAI titers at day 0 (pre-vaccine), 30 days post-vaccine, and 6 months post 
vaccine. HAI titers fold change was measured between day 0 – 30 day and 30 day – 6-
month time points and prevalence of seroprotection and seroconversion were found. All 
data was analyzed on Prism GraphPad Version 7. 
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3. Results 
3.1 ELISA Data: Antibody response may be influenced by metabolic state  
Antibody response at Day 0 across the three groups was similar with no significant 
differences. As expected all three groups exhibited their lowest antibody response prior to 
vaccination. Thirty days post vaccination, healthy weight individuals and obese 
nondiabetics responded similarly to the virus but obese diabetics had a trend towards a 
higher percent change in their response (p=0.06) (Figure 5.4). While the trend is visibly 
clear on the graph (Figure 5.3), there was no significant difference in antibody responses 
between the three groups (p=0.09). All groups showed a decreased response 6 months 
post-vaccination as compared to 30 days post-vaccination. There was no association 
between ELISA measured antibody response and menopausal status (p=0.438) or BMI 
(p=0.627) but there was a significant difference in the antibody response 30 days post-
vaccination in subjects taking metformin (p=0.04) (Table 5.2).  
3.2 HAI Data: Antibody response not associated with differences among the groups 
When measuring for all antibodies that would mount a protective response to the virus, 
there were no significant differences between the three groups (p=0.32) (Figure 5.5). 
However, those with the highest HAI titers across the entire sample size were also in the 
obese diabetic group. When measuring for fold-change in HAI titer across the three 
groups the results were insignificant, for both fold-increase Day 0-30 Days (Figure 5.6, 
p=0.89) and fold-decrease 30 Days-6 Months (Figure 5.7, p=0.35).  
There was no association between HAI measured antibody response and menopausal 
status (p=0.96), BMI (p=0.99), or metformin use (p=0.35) (Table 5.2). 
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4. Discussion 
After the 2009 flu pandemic, it was found that obesity is an independent risk factor for 
morbidity and mortality from influenza7 and Sheridan et al. reported that obesity 
impaired the adaptive immune response to the influenza vaccine2. Given that obesity and 
type-2 diabetes are closely associated, in Sheridan et al. published a study examining the 
immune response to the influenza vaccine of diabetic individuals5. Interestingly however, 
there were no significant differences in the immune response of diabetic and non-diabetic 
subjects. One important distinction to make between obese non-diabetics and obese 
diabetics is that many obese type-2 diabetics are taking metformin6, which is known to 
improve their metabolic state and could potentially improve their immune cell function13.  
4.1 Metformin could be associated with improved adaptive immune responses 
Based on the findings of this study, the ELISA data suggests that obese diabetic subjects 
taking metformin had a higher antibody response than both healthy weight and obese 
nondiabetic individuals (Figure 5.3). This indicates that there may be a link between 
metformin use and antibody response, given that the obese diabetic subjects were the 
only group taking the drug. However, the HAI antibody response data does not reinforce 
these findings because the obese diabetic group did not display any significant 
differences in their response to the virus as compared the other two groups (Figure 5.5). It 
is interesting to point out, though, that only in the obese diabetic group were 100% of the 
subjects seroprotected 30 days post vaccination (Table 5.10). These findings suggest the 
potential of metformin aiding the immune response of obese individuals.  
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According to the recently published researched, metformin may actually help the 
immune cells respond to the influenza virus. The mechanism by which this is happening 
is not entirely clear but there are some suggestions in the literature. One study suggests 
that metformin blocks a specific signal transduction pathway linked to glucose and 
anabolic metabolism that ultimately activates NF-κB. In this regard, metformin improves 
CD8 T-cell memory by modulating fatty acid metabolism.13Metformin is currently being 
used as an immunemodulator for tuberculosis, although it is not clear what cells 
metformin is targeting.14 Additionally, metformin is used for anti-tumor effects  through 
inhibiting mitochondrial complex I in the electron transport chain.14 These are all 
promising points to suggest that metformin could play an important role in modulating 
the adaptive immune response, but more research needs to be done to better understand 
this relationship.  
4.2 Peak antibody response does not correlate with peak of flu season 
This study found that all three groups had a lower response to the influenza virus 6 
months post vaccination as compared to 30 days post vaccination (Figure 5.3). 
Considering that many people get their vaccination in early September, when the flu 
vaccine is first made available, they may not be as protected by the time the peak of the 
flu season hits. In North Carolina, during the 2016-17 flu season, circulation of the virus 
peaked in early March and again at the beginning of April16, about 6 – 7 months after the 
flu vaccine was released to the public. This could mean that those who were vaccinated 
early in the season may not be as well protected as they would have been had they been 
vaccinated closer to the peak of the season. However, during the 2014-15 flu season, the 
influenza illnesses peaked at the beginning of January.  
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4.3 Strengths and Limitations 
This study used two proven methods of measuring antibody response and the same 
positive control was used on every plate. The antibody response was also found over 
varying time points to help create a timeline. This helped us determine that the peak 
antibody response for our subjects did not correlate with the peak of the flu activity. We 
also used medical records and current serum glucose levels to identify diabetics and 
metabolically healthy obese individuals. 
There were several weaknesses of this study. The duration of diabetes was not 
considered in study subjects. It is possible that the length of time the subjects had 
diabetes had an effect on their immune response. The sample size was small (n=15), 
making the data underpowered. The study only represented white non-Hispanic women 
ages 37-58. The subjects’ serum was tested for response to one virus, but the vaccine that 
they were given was trivalent. It could have been that subjects responded differently to 
different vaccine strains, but that was not captured in the scope of this study.  
4.4 Future Research 
Because of the abundance of evidence in the literature to suggest that metformin has 
beneficial effects on the immune cells, it is important to look further into how metformin 
specifically affects the adaptive immune cell function. This can be done collecting more 
in-depth metabolic data, including T-cell and B-cell metabolism, respiration rates and the 
fuel sources they are using to generate energy. It is also important to investigate the 
effects of metformin on antibody response in a more diverse group of people. To ensure a 
larger sample size, mouse models could also be used to investigate metformin in a more 
controlled environment.  
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5. Figure and Charts 
 
Table 1. Demographic data of study subjects 
 
Variable	 		 HW	 OH	 OD	
Sex	-	no.	(%)	 	 	 	 		Female	 	 6	(100.0)	 5	(100.0)	 4	(100.0)	
Age	-	yr	 	 	 	 		Mean	±	Std	 	 48	±	7	 51	±	6	 49	±	11	Range	 	 40	-	58	 44	-	57	 37	-	58	
Race	-	no.	(%)	 	 	 	 		White	 	 6	(100.0)	 5	(100.0)	 4	(100.0)	
Ethnicity	-	no.	(%)	 	 	 	 		Non-Hispanic	 		 6	(100.0)	 5	(100.0)	 4	(100.0)	
 
 
Table 2. ELISA and HAI antibody related to menopausal status, BMI and metformin use 
 
 
 
  
    Menopausal BMI Metformin Antibody 
HAI Titer    
Day 0 95% CI (-0.634, 0.3944) (-0.6057, 0.4324) (-0.1577, 0.7641) (-0.4416, 0.5985) 
  p-value 0.605 0.673 0.143 0.7027 
30 Day  (-0.5004, 0.5478) (-0.5272, 0.5218) (-0.2772, 0.7066) (-0.5787, 0.4657) 
   0.961 0.992 0.352 0.7823 
6 month  (-0.3684, 0.6519) (-0.5111, 0.5376) (-0.3657, 0.6536) (-0.3189, 0.6829) 
   0.479 0.950 0.519 0.3721 
Antibody    
Day 0 95% CI (-0.4773, 0.5687) (-0.5271, 0.5219) (-0.1355, 0.7734) - 
  p-value 0.864 0.995 0.138 - 
30 Day  (-0.6679, 0.3436) (-0.4185, 0.6164) (0.04851, 0.8378) - 
  
 
0.438 0.627 0.037 - 
6 month 
 
(-0.5687, 0.4773) (-0.448, 0.5934) (-0.1355, 0.7734) - 
    0.864 0.724 0.138 - 
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 Figure 5.3 
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Figure 5.5  
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Figure 5.816 
 
 
 
 
Figure 5.916 
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Table 5.10 HAI: Seroprotection and Seroconversion of the Three Groups Post 
Vaccination 
  
Seroprotected HW OH OD 
30 Days 60% 80% 100% 
6 Months 60% 60% 50% 
        
Serconverted HW OH OD 
30 Days 0% 40% 0% 
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